Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|January 10, 2024
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experienceOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Transplantation and Cellular Therapy|June 9, 2024
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three DecadesOren Pasvolsky, Curtis Marcoux, Jianliang Dai, et al.
Transplantation and Cellular Therapy|May 18, 2025
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous TransplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Transplantation and Cellular Therapy|August 2, 2025
Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell TransplantCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Transplantation and Cellular Therapy|May 5, 2022
Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation CyclophosphamideRohtesh S Mehta, Rima M Saliba, Sassine Ghanem, et al.
Blood Cancer Journal|November 1, 2024
Optimal infused CD34<sup>+</sup> cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantationOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Bone Marrow Transplantation|December 5, 2025
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myelomaOren Pasvolsky, Curtis Marcoux, Denái R Milton, et al.
Leukemia|September 20, 2022
Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapyPaolo Strati, Andrew P Jallouk, Ryan Sun, et al.
Blood Cancer Journal|May 3, 2023
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patientsOren Pasvolsky, Denái R Milton, Mikael Rauf, et al.
Transplantation and Cellular Therapy|January 2, 2025
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell TransplantationOren Pasvolsky, Curtis Marcoux, Zhongya Wang, et al.
Pageof 6